Farallon Capital Management has established a new position in Thermo Fisher Scientific (TMO), according to a recent SEC filing. The investment firm purchased 881,490 shares, valued at approximately $433.28 million, giving it a 2.47% weight in its reported portfolio. The stake was established during the first quarter of 2026, a period in which Thermo Fisher reported a 6% increase in revenue to $11.01 billion and raised its financial guidance for the year.
As with all 13F filings, this disclosure is delayed; it reflects the firm's holdings as of March 31, 2026, though the information was made public on August 14. During its first quarter, Thermo Fisher reported strong performance and highlighted robust demand from its pharmaceutical and biotech customers as a key driver of growth.